Therapeutic use of pituitary oesensitization with a long-acting LHRM agonist: A potential new treatment for idiopathic precocious puberty

W. F. Crowley, F. Comitf, W. Vale, J. Rivier, D. L. Loriaux, G. B. Cutler

Research output: Contribution to journalArticlepeer-review

188 Scopus citations

Abstract

A two year girl with idiopathi true precocious puberty was treated with a long-acting(LHRH) agonist, D–Trp6 –Pro9 –NEt–LHRH (LHRHa). Prior to therapy, the patient demonstrated pulsatile gonadotropin Prior to therapy, the patient demonstratedpulsatile gonadotropin secretion during both night and day, a pubertal response to exogenous LHRH, and an elevated plasma estradiol level. After eight weeks of therapy (4 [g/kg daily), mean gonadotropin levels fell to the prepubertal range, there was no evidence of pulsatile discharge of gonadotropins nor any response to exogenous LHRH, and plasma estradiol levels became undetectable. No adverse drug reactions were encountered and all effects of therapy were reversed following cessationof treatment for two months. LHRH analogs may offer a nev; approach to the therapy of idiopathic precocious puberty and merit further study.

Original languageEnglish (US)
Pages (from-to)370-372
Number of pages3
JournalJournal of Clinical Endocrinology and Metabolism
Volume52
Issue number2
DOIs
StatePublished - Feb 1981

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Therapeutic use of pituitary oesensitization with a long-acting LHRM agonist: A potential new treatment for idiopathic precocious puberty'. Together they form a unique fingerprint.

Cite this